Specialties
Reports that name this provider
- Alternative Cancer Treatment Availability in United States
- Led by Dr. Stanislaw Burzynski. Offers antineoplaston therapy. FDA placed the research institute's IND application under a full clinical hold, meaning no new clinical trial enrollments are permitted. The clinic's financial position is described as insolvent absent Dr. Burzynski's personal funding. Subject to FDA enforcement, Texas Medical Board proceedings (2017 recommendation to revoke license resulting in $360,000 fine).